Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel
NEJM 342:1773-1777,1824, Bennett,C.L.,et al, 2000
Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine Use,A Report of 3 Cases and Review of the Literature
Arch Int Med 159:311-314, Chen,D.K.,et al,, 1999
Thrombotic Thrombocytopenic Purpura Assoc with Ticlopidine, Review of 10 Cases
Ann Int Med 128:541-544, Bennett,C.L.,et al, 1998
Pilot Trial of Immunoglobulin Versus Plasma Exchange in Patients with Guillain-Barre Syndrome
Neurol 46:100-103, Bril,V.,et al, 1996
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Relapse in Guillain-Barre Syndrome after Treatment with Human Immune Globulin
Neurol 43:872-875, 8571993., Inrani,D.N.,et al, 1993
Human Immune Globulin Infusion in Guillain-Barre Syndrome:Worsening During & After Treatment
Neurol 43:1034-1036, 8571993., Castro,L.H.M.&Ropper,A.H., 1993
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991